COVID-19: cytokine storm and anticytokine therapy
Keywords:COVID-19, pro-inflammatory cytokine, anti-inflammatory cytokines, systemic inflammatory response, cytokine storm, acute respiratory distress syndrome, hypercoagulation, mononuclear macrophages, anti-cytokine therapy, glucocorticoids, turmeric-based drugs, review
This review describes in detail one of the key links in the pathogenesis of COVID-19 — the overproduction of pro-inflammatory cytokines that play a key role in the formation of acute respiratory distress syndrome, disseminated intravascular coagulation, multiple organ dysfunction syndromes, and causes high mortality among patients infected with COVID-19. The article deals with the basic directions of intensive therapy for the prevention of development as well as the treatment of cytokine storm and drugs for anti-cytokine therapy. Among drugs with anti-cytokine and anti-inflammatory properties, corticosteroids have the highest evidence base for efficacy and safety. The most promising drugs that require further clinical studies are those that inhibit the activity of the main intracellular regulator of the production of proinflammatory cytokines, the nuclear transcription factor kappa B of immunocompetent cells. These include turmeric-based preparations, which are now at the final stages of the pre-registration studies.
Qing Ye, Bili Wang, Jian Hua Mau. Pathogenesis and Treatment of the “Cytokine Storm” in COVID-19. Journal of Infection. 2020. 80. 607-613.
Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association An update on the Epidemiological characteristics of novel Coronavirus Pneumonia (COVID-19). Clin. J. Epidemiol. 2020. 4.
Chousterman B.G. еt al. Cytokine storm and sepsis disease pathogenesis. Seminors Immunopatholog. 2017. 39(5). 517-28.
Channapanavar R. et al. Disregulate Type 1 Interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-Cov infected Mice. Cell. Host. Microbe. 2016. 19(2). 181-93. PubMed PMID: 26867177.
Карл Дреслер. Иммунология (словарь): пер. с нем. К.: Вища школа, 1988. 224 с.
Davidson S. et al. Disease-promoting effects of Type 1 Interferons in viral, bacterial and coinfection. J. Interf. Cytokine Res. 2015. 35(4). 352-64. PubMed PMID: 25714109.
Shaw A.C. et al. Are-dependent dysregulation of innate immunity. Nature Rev. Immunolog. 2013. 13(12). 875-87. PubMed PMID: 24157572.
Law H.K.W. et al. Chemokine up-regulation in SARS-coronaqvirus-infected, monocyte-derived human dendritic cells. Blood. 2005. 106(7). 2366-74. PubMed PMID: 15860669.
Cheung C.Y. et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J. Virol. 2005. 79(12). 7819-26. PubMed PMID: 15919935.
Tynell J. et al. Middle East respiratory syndrome coronavirus shaws poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J. Gen. Virol. 2016. 97(2). 344-55. PubMed PMID: 266022089.
Zhou J. et al. Active replication of Middele East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implication to pathogenesis. J. Infect. Diseases. 2014. 209(9). 1331-42. PubMed PMID: 24065148.
Scheuplein V.A. et al. High secretion of interferons by human plasmocytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. J. Virol. 2015. 89(7). 3859-69. PubMed PMID: 25609809.
Lau S.K.P. et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implication for pathogenesis and treatment. J. Gen. Virol. 2013. 94(Pt. 12). 2679-99. PubMed PMID: 24077366.
Smits S.L. et al. Exacerbated innate host response to SARS-CoV in aget non-human primates. PLoS Pathogens. 2010. 6(2). 100075. PubMed PMID: 20140198.
Ng D.L., Al Hossani et al. Clinicopathologic, immunohystochemical and ultrastructural findings of a fatal case Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am. J. Pathol. 2016. 186(3). 652-8. PubMed PMID: 26857507.
Chien J.Y. et al. Temporal changes in cytokine/chemokine profiles and pulmonary involment in severe acute respiratory syndrome. Respirol. (Сarlton, Vic). 2006. 11(6). 715-22. PubMed PMID: 17052299.
Wong C.K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exper. Immunol. 2004. 136(1). 95-103. PubMed PMID: 15030519.
Huang C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, Chine. Lancet. 2020. 395(10223). 497-506.
Marchingo J.M. et al. Quantitative analysis of how Mic controle T-cell proteomes and metabolic pathway during T-cell activation. eLife. 2020. 9. 53725.
Chen L. et al. Analisis of clinic features of 29 patients with 2019 novel coronavirus pneumonia. Chin. J. Tuberc. Respir. Dis. 2020. 43.
Yang K. et al. Clinical course and out comes of critical ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered retrospective observational study. Lancet Respirat. Med. 2020. 2213-600. PubMed PMID: 32105632.
Force TADT Acute respiratjry distress syndrome: the berlin definition. JAMA. 2012. 307(23). 2526-33.
Ho J.C. et al. High-dose puls versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am. J. Resp. Crit. Care Med. 2003. 168(2). 1449-56. PubMed PMID: 12947028.
Auyeung T.W. et al. The used of corticosteroid as treatment in SARS was associated with adverse outcomes: а retrospective cohort study. J. Infect. 2005. 51(2). 98-102. PubMed PMID: 16038758.
Villar J., Ferrando C., Martinez D. et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir. Med. 2020. 8. 267-276.
The WHO Rapid Evidence for COVID19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically ill Patients With COVID-19. A Metaanalisis. JAMA. 2020 Oct 6. 324(13). 1330-1341. Doi: 10.1001/Jama.2020.17033.
Bruno M. Tomazini, Israel S. Maia, Cavalcanti A.B. et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19. The CoDEX Randomized Clinical Trial. JAMA. 2020. 324(13). 1307-1316. Doi: 10.1001/Jama.2020. 17021.
Deqin P.F., Heming N., Meziani F. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically ill Patients With COVID-19. JAMA. 2020. 324(13). 1298-1306. doi: 10.1001/Jama.2020.
The Writing Committee for the REMAP-CAP investigators Effect of Hydrocortisone of Mortality and Organ Support in Patients with Severe COVID-19. The REMAP-CAP COVID-19 Corticosteroid Domain Randomised Clinical Trial. JAMA. 2020 Oct 6. 324(13). 1317-1329. doi: 10.1001/Jama.2020.
Zhao J.P. Expert consensus on the use of corticosteroid in patients with 2019-n Cov pneumonia. Chin. J. Tuberc. Respir. Dis. 2020.
Zhao J.P. Effectiveness of glucorticosteroid therapy in patients with severe novel coronavirus pneumonia: protocol of randomized controlled trial. Chin. Med. J. 2020.
Tleyjeh I.M. et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2020.10.036.
Stone J.H., Frigault M.J., Serling-Boyd N.J. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. 2020. 383(24). 2333-2344. doi: 10.1056/NEJMoa2028836.
Michael S. Saag et al. Misquided Use of Hydroxychloroqine for COVID-19. The Infusion of Politics Into Science. Jama. 2020. 324(21). 2161-2162.
Borda M.G.S., Almaida F.F., Sampio V.S. et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2) Infection. A Randomized Clinical Trial. Jama Network Open. 2020. 3(423).
Fihn S.D., Perencevich E., Bredley S.M. Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronovirus Disease 2019. Jama Network Open. 2020. 3(423). e209035.
Self Wesley H., Sember M.W., Lether L.M. et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19. A Randomized Clinical. Trial. JAMA. 2020. 324(21). 2165-2176. doi: 10.1001/Jama.2020.
Wen-tao Meng, Long Qing, Chum-Zen Li et al. Ulinastatin: A Potential Alternative to Glucocorticoid in the Treatment of Severe Decompression Sickness Frontiers in Physiology. March 2020(11). Article 273.
Xiangiun Zang, Zhaozhong Zhy, Wei Liu et al. Ulinastatin treatment for acute respiratory distress syndrome in Chine: meta-analisis of randomized controlled trial. BMC Pulmonary Medicine. 2019. 19. 196.
Hai Huang, Ping-Fang Hu, Liang-Liang Sun et al. Treatment of COVID-19 Patients With High Dose of Ulinastatin. Changzheng Hospital. https://orcid.org/0000-0002-7137-112X.
Manoharan Y., Haridas V., Vasanthakumar K.C. et al. Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management. Indian J. Clin. Biochem. 2020 Jul. 35(3). 373-375.
Geng et al. Curcumin attenuates BPA-induced insulin resistance in Hep G2 cells through suppretion of JNK/p38 pathways. Toxicol. Lett. 2017. 272. 75-83.
Varna S.R. et al. Imiquimod-induced Psoriasis-like inflammation in differentiated Human keratocytes: its evaluation using curcumin. Eur. J. Pharmacol. 2017. 813. 33-41.
Devi Y.S. et al. Ingibition of IL-6 signaling pathway by curcumin in uterine decidual cells. Plos ONE. 2015. 10. e0125627.
Panahi Y. et al. A randomized controlled trial on the anti-inflamatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann. Clin. Biochem. 2012. 49. 580-588.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.